OSI Pharmaceuticals (OSIP) Initiates Phase I Trial for OSI-027 in Patients with Lymphoma
More News related to OSIP
- OSI Pharmaceuticals (OSIP) Said Tarceva Endorsed by the U.K.s National Institute for Health and Clinical Excellence
- Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
- OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 4th
- OSI Pharmaceuticals to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
- Unusual 11 Mid-Day Movers 11/19: LPX, SRS, SKF, OSIP Higher; GNVC, LZB, LNC, GCO Lower
More News related to Corporate News
- Citigroup Cuts Estimates and Price Target on Amazon.com (AMZN) Due To Flat Online Retail Growth
- GMP Cuts Price Target on Research In Motion (RIMM) to $80
- Deutsche Bank Lowers Estimates and Price Target on General Electric (GE)
- Another Anaylst Comes to RIM's (RIMM) Defense; Reiterates Buy
- RBC Cuts Price Target on RIM (RIMM) to $45
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) has initiated a Phase I clinical trial of OSI-027, an oral, potent and selective inhibitor of both the TORC1 and TORC2 complexes that inhibits the kinase activity associated with mTOR (mammalian target of rapamycin). The study is designed to determine the maximum tolerated dose (MTD) and to establish the recommended dose and dosing schedule for Phase II trials, and will evaluate the safety and pharmacokinetic profiles of OSI-027.
Preclinical studies demonstrated that orally administered OSI-027 has the potential for anti-tumor efficacy in a broad range of human cancers that depend on the mTOR pathway for tumor growth and survival, such as ovarian, colorectal, breast, lung, prostate and brain cancers, in addition to lymphoma.
“OSI-027 has the potential to be the next generation modulator of mTOR signaling by providing both TORC1 and TORC 2 inhibition, versus rapalogs that inhibit only TORC1 activity,” said Karsten Witt, M.D., Vice President, Clinical Development Oncology and Drug Safety, OSI Pharmaceuticals. “OSI-027 was fully discovered at OSI and we are encouraged by the pre-clinical data that also suggest that OSI-027 may show enhanced activity in combination with other molecular therapies, including Tarceva® (erlotinib).”[SM]
Related Categories
Corporate NewsStocks Mentioned
-0.52Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
